Business Wire

MA-VERACODE

Share
Healthcare Sector Leads the Way for Fix Rate of Software Security Flaws

Veracode, a leading global provider of application security testing solutions, today revealed that the healthcare sector takes first place for the proportion of software security flaws that are fixed, at 27 percent. The sector overtook financial services as the top-performing industry, demonstrating healthcare providers have made good headway toward the goal of making their software more secure over the past year.

The data was published in the company’s annual State of Software Security (SoSS) report v12, which analyzed 20 million scans across half a million applications in the healthcare, financial, technology, manufacturing, retail, and government sectors.

Chris Eng, Chief Research Officer at Veracode, said, “Healthcare is one of the more highly regulated sectors and is considered critical infrastructure by the government, so it’s encouraging to see the sector performs comparatively well in terms of overall flaw remediation. We hope healthcare developers and IT staff see this as a welcome ray of sunshine amidst the all-too-often gloomy realm of software security. There is still work to do, so here’s to more improvements in the years to come.”

Despite taking the top spot for fix rate, 77 percent of applications in the healthcare industry contain vulnerabilities, with 21 percent of applications containing high severity vulnerabilities. The sector also has ample room for improvement in terms of the time spent to fix flaws once they’re detected, taking up to a whopping 447 days to reach the halfway point of remediation.

Healthcare Breach Costs Are the Most Expensive

With healthcare companies incurring the highest average breach costs, at a new record high of $10.1 million*, taking proactive steps to minimize the risk of a cyberattack is imperative. Since data breaches in highly regulated industries tend to be associated with larger long-term costs that accrue over the ensuing years, the industry would benefit from even greater comprehensive efforts to address security earlier in the software development lifecycle.

Of the six industries analyzed, healthcare providers rank toward the bottom for the proportion of applications with any flaws, and second to last for the percentage of high-severity flaws—defined as those that present a serious risk to the application and organization if they were to be exploited. When it comes to the types of flaws discovered from dynamic analysis of applications in the sector, compared to other industries healthcare providers perform well for authentication issues and insecure dependencies, but have a higher incidence of cryptographic and deployment configuration issues.

Eng said, “We know that no application will ever be 100 percent free of security flaws, so it’s important that businesses take all necessary steps to minimize risk as much as possible. This includes scanning at a regular, rapid pace using multiple testing types, integrating testing tools into developer environments, and providing hands-on training to help developers understand the origin of flaws and how to fix or prevent them entirely. The healthcare sector should also take extra care to prioritize critical flaws—those vulnerabilities that could have a catastrophic impact if left unaddressed for too long.”

Andrew McCall, Vice President of Engineering, Azalea Health Innovations, said, “The biggest obstacle to building security into our workflows is that developers will treat security as just a checkbox. But security is an ongoing process and has to be top of mind throughout the software development life cycle. We chose Veracode because it was the easiest and best solution when it comes to integrating into our existing processes.”

Third-party Library Security

Considering a sharp increase in regulations to secure the software supply chain over the past year, the report analyzed third-party libraries to identify how vulnerabilities discovered through software composition analysis (SCA) behave. Overall, around 30 percent of vulnerable libraries remain unresolved after two years; however, that statistic reduces to 25 percent for the healthcare sector. In fact, while the overall ratio of vulnerable libraries found by SCA trends down steadily over time, healthcare experienced a brief upward spike before driving rates down dramatically over the last year or so.

The Veracode State of Software Security v12 healthcare snapshot is available to download here and the full report is available here.

* IBM Security and The Ponemon Institute, “Cost of a Data Breach Report 2022”: https://www.ibm.com/downloads/cas/3R8N1DZJ, July 2022

About the State of Software Security Report

The Veracode State of Software Security (SoSS) v12 analyzed the full historical data from Veracode services and customers. This accounts for a total of more than half a million applications (592,720) that used all scan types, more than a million dynamic analysis scans (1,034,855), more than five million static analysis scans (5,137,882) and more than 18 million software composition analysis scans (18,473,203). All those scans produced 42 million raw static findings, 3.5 million raw dynamic findings, and six million raw SCA findings.

The data represents large and small companies, commercial software suppliers, software outsourcers, and open-source projects. In most analyses, an application was counted only once, even if it was submitted multiple times as vulnerabilities were remediated, and new versions uploaded.

About Veracode

Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.

Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005100/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release

Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e

Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release

News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye